中国眼科医疗设备行业正面临结构性机遇与挑战。疾病谱的深刻变化构成了市场增长的刚性基本盘：一方面，人口老龄化持续推高中老年眼病患者基数，中国白内障与青光眼患者分别高达约2800万人与2100万人，合计占全球患者比例超过四分之一；另一方面，青少年近视呈现“高发、低龄化”特征，中国近视患者规模约7.5亿人，加之糖尿病等慢性病管理带来的眼底病变风险，共同驱动眼科诊疗需求从“治已病”向“防未病”的战略前移。
面对庞大的疾病负担，眼科设备市场在政策引导与技术突破下进入高速发展期。国家“十四五”眼健康规划及近视防控战略强力推动了筛查网络建设与设备普及，而技术创新则成为产业升级的核心引擎。以眼科OCT、光学生物测量仪为代表的诊断设备正向更高精度、更快速度与更智能分析演进。同时，国产化替代进程显著加速，本土企业凭借对核心技术的攻克与更高的性价比，已在眼科OCT、光学生物测量仪等细分领域形成有力竞争。
展望未来，行业增长动力将更加聚焦于“基层普及”与“价值延伸”。在分级诊疗体系完善与普惠医疗政策推动下，便携化、自动化、智能化的眼健康筛查设备将加速下沉至社区、校园等基层场景，赋能大规模早期筛查。与此同时，人工智能与光学技术的深度融合，正推动设备从单一的诊断工具，升级为集筛查、诊断、随访管理于一体的“全周期眼健康解决方案”，行业生态从产品制造向可持续的健康服务模式演进。
The ophthalmic medical equipment industry in China is currently facing both structural opportunities and challenges. Profound shifts in the disease spectrum provide a solid foundation for market growth: on one hand, the aging population continues to expand the population of middle-aged and elderly patients with ophthalmic diseases—China has approximately 28 million cataract patients and 21 million glaucoma patients, together accounting for more than a quarter of the global patient population; on the other hand, myopia among children and adolescents is becoming increasingly prevalent and occurring at younger ages, with around 750 million people affected in China. In addition, the rising risk of diabetic and other chronic disease-related retinal complications is further driving ophthalmic care demand to shift from disease treatment toward prevention, early detection, and long-term management.
Against this backdrop of a substantial disease burden, the ophthalmic equipment market has entered a period of rapid growth, propelled by policy guidance and technological breakthroughs. The national “14th Five-Year Plan” for eye health and myopia prevention initiatives strongly support the establishment of screening networks and equipment deployment, while technological innovation serves as the core engine for industry upgrading. Diagnostic devices, such as ophthalmic OCT and optical biometry instruments, are evolving toward higher precision, faster operation, and more intelligent analytical capabilities. Meanwhile, the pace of domestic substitution has accelerated significantly, with local companies leveraging advances in core technologies and superior cost-effectiveness to establish strong competitiveness in segments such as OCT and optical biometry.
Looking ahead, industry growth will increasingly focus on “primary-level accessibility” and “value extension.” With the improvement of the hierarchical medical system and the promotion of inclusive healthcare policies, portable, automated, and intelligent eye screening devices are expected to penetrate community and school settings, enabling large-scale early screening. At the same time, the deep integration of artificial intelligence and optical technologies is transforming devices from single-purpose diagnostic tools into comprehensive, full-cycle eye health solutions that encompass screening, diagnosis, and follow-up management. The industry ecosystem is thus evolving from product manufacturing toward sustainable health service models.
